Association of survival with stereotactic body radiation therapy following induction chemotherapy for unresected locally advanced pancreatic cancer.
Publication/Presentation Date
9-1-2022
Abstract
BACKGROUND: Induction chemotherapy (iC) followed by concurrent chemoradiation has been shown to improve overall survival (OS) for locally advanced pancreatic cancer (LAPC). However, the survival benefit of stereotactic body radiation therapy (SBRT) versus conventionally fractionated radiation therapy (CFRT) following iC remains unclear.
METHODS: The National Cancer Database (NCDB) was queried for primary stage III, cT4N0-1M0 LAPC (2004-2015). Kaplan-Meier analysis, Cox proportional hazards method, and propensity score matching were used.
RESULTS: Among 872 patients, 738 patients underwent CFRT and 134 patients received SBRT. Median follow-up was 24.3 months and 22.9 months for the CFRT and SBRT cohorts, respectively. The use of SBRT showed improved survival in both the multivariate analysis (HR 0.78, p=0.025) and 120 propensity-matched pairs (median OS 18.1 vs 15.9 months, p=0.004) compared to the CFRT.
CONCLUSION: This NCDB analysis suggests survival benefit with the use of SBRT versus CFRT following iC for the LAPC.
Volume
21
Issue
3
First Page
403
Last Page
410
ISSN
1460-3969
Published In/Presented At
Ma, S. J., Serra, L. M., Bartl, A. J., Han, H. R., Fekrmandi, F., Iovoli, A. J., Prezzano, K. M., Hermann, G. M., Yu, H., & Singh, A. K. (2022). Association of survival with stereotactic body radiation therapy following induction chemotherapy for unresected locally advanced pancreatic cancer. Journal of radiotherapy in practice, 21(3), 403–410. https://doi.org/10.1017/s1460396921000212
Disciplines
Medicine and Health Sciences
PubMedID
36016862
Department(s)
Fellows and Residents
Document Type
Article